See more : Paramount Global (VIACA) Income Statement Analysis – Financial Results
Complete financial analysis of Addex Therapeutics Ltd (ADXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Addex Therapeutics Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Immobiliere Dassault SA (IMDA.PA) Income Statement Analysis – Financial Results
- Pitti Engineering Limited (PITTIENG.BO) Income Statement Analysis – Financial Results
- Fuji Media Holdings, Inc. (FJTNY) Income Statement Analysis – Financial Results
- UTStarcom Holdings Corp. (UTSI) Income Statement Analysis – Financial Results
- FG Merger Corp. (FGMCW) Income Statement Analysis – Financial Results
Addex Therapeutics Ltd (ADXN)
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | 6.04M | 499.89K | 17.33K | 40.30K | 85.40K | 91.76K | 121.09K | 2.82M | 1.98M | 4.09M | 26.81M | 486.93K | 4.74M |
| Cost of Revenue | 6.94M | 14.62M | 12.82M | 10.37M | 230.10K | 144.17K | 29.76K | 17.33K | 40.30K | 85.40K | 91.76K | 1.27M | 27.99M | 31.16M | 0.00 | 0.00 | -156.03K | 0.00 |
| Gross Profit | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | 5.90M | 470.13K | 0.00 | 0.00 | 0.00 | 0.00 | -1.15M | -25.16M | -29.19M | 4.09M | 26.81M | 642.96K | 4.74M |
| Gross Profit Ratio | -329.99% | -928.06% | -339.55% | -187.12% | 91.67% | 97.61% | 94.05% | 0.00% | 0.00% | 0.00% | 0.00% | -948.14% | -891.19% | -1,477.75% | 100.00% | 100.00% | 132.04% | 100.00% |
| Research & Development | 2.75M | 14.67M | 12.84M | 10.37M | 12.45M | 2.37M | 841.31K | 819.33K | 761.22K | 258.06K | 2.22M | 4.76M | 4.76M | 31.16M | 39.96M | 44.19M | 12.21M | 9.77M |
| General & Administrative | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Other Expenses | 1.94M | -22.52K | 444.00K | 336.68K | 648.17K | 382.99K | 197.67K | 799.70K | 311.82K | -9.44K | 5.77M | 9.40M | -919.55K | -2.02M | 0.00 | -67.33K | 25.90M | 15.98M |
| Operating Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 5.81M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Cost & Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 33.80M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Interest Income | 63.96K | 29.25K | 5.32K | 35.31K | 36.87K | 85.87K | 0.00 | 27.00 | 39.86K | 1.59K | 4.13K | 22.66K | 72.20K | 97.25K | 362.13K | 3.31M | 2.55M | 241.99K |
| Interest Expense | 21.61K | 48.90K | 63.01K | 69.50K | 128.52K | 220.17K | 45.35K | 6.92K | 152.21K | 0.00 | 0.00 | 0.00 | 239.37K | 144.81K | 0.00 | 501.88K | 8.54K | 30.45K |
| Depreciation & Amortization | 305.95K | 323.14K | 347.61K | 378.75K | 333.84K | 2.94K | 15.25K | 25.76K | 25.88K | 110.14K | 662.55K | 2.10M | 2.93M | 2.94M | 2.84M | 2.02M | 1.80M | 2.52M |
| EBITDA | -10.23M | -20.23M | -14.94M | -12.41M | -14.32M | -1.51M | -3.22M | -3.12M | -2.61M | -1.71M | -13.79M | -24.87M | -28.05M | -30.56M | -39.86M | -19.55M | -33.26M | -17.99M |
| EBITDA Ratio | -634.16% | -1,417.83% | -519.59% | -327.42% | -515.18% | -23.52% | -644.10% | -17,979.05% | -6,488.51% | -1,998.26% | -15,026.90% | -20,542.67% | -990.78% | -1,547.10% | 1,112.94% | -72.92% | -6,833.66% | -380.48% |
| Operating Income | -10.28M | -20.52M | -15.51M | -12.24M | -14.83M | -1.42M | -3.24M | -3.13M | -3.87M | -1.80M | -14.46M | -27.01M | -30.97M | -33.60M | -43.05M | -24.87M | -37.62M | -20.90M |
| Operating Income Ratio | -637.42% | -1,442.61% | -531.70% | -338.88% | -536.92% | -23.57% | -647.15% | -18,059.88% | -9,597.64% | -2,103.69% | -15,756.97% | -22,306.25% | -1,097.02% | -1,700.93% | -1,052.47% | -92.78% | -7,726.28% | -441.03% |
| Total Other Income/Expenses | -274.93K | -284.01K | 154.00K | -615.33K | -176.45K | -220.17K | -45.35K | -19.79K | -1.56M | 748.35K | -3.23K | -8.41K | -167.17K | -47.56K | 85.75M | 2.81M | 2.54M | 355.32K |
| Income Before Tax | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | 42.69M | -22.07M | -35.09M | -20.54M |
| Income Before Tax Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | 1,043.62% | -82.32% | -7,205.50% | -433.53% |
| Income Tax Expense | 0.00 | 123.91K | 116.38K | 207.76K | 429.01K | 1.00 | 0.00 | 6.92K | 152.21K | -21.68K | 3.23K | -398.93K | 72.20K | 97.25K | 171.13M | 3.31M | 2.54M | 346.91K |
| Net Income | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | -42.69M | -22.07M | -35.09M | -20.54M |
| Net Income Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | -1,043.62% | -82.32% | -7,205.50% | -433.53% |
| EPS | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| EPS Diluted | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| Weighted Avg Shares Out | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
| Weighted Avg Shares Out (Dil) | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2021 Results - Earnings Call Transcript
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2021 Results - Earnings Call Transcript
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -25.76% and 16.29%, respectively, for the quarter ended December 2021.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade
Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of 0.00% and 96.43%, respectively, for the quarter ended September 2021.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
New Strong Sell Stocks for August 20th
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -18.46% and 352.31%, respectively, for the quarter ended June 2021.
Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?
Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2020 Results - Earnings Call Transcript
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2020 Results - Earnings Call Transcript
Enamine Extend Collaboration With Prominent Swiss Biotech
KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and...
Source: https://incomestatements.info
Category: Stock Reports